Cargando…
Efficacy of Combination Therapy with the JAK Inhibitor Baricitinib in the Treatment of COVID-19
Coronavirus disease-19 (COVID-19), resulting from infection with SARS-CoV-2, spans a wide spectrum of illness. In severely ill patients, highly elevated serum levels of certain cytokines and considerable cytolytic T cell infiltrates in the lungs have been observed. These same patients may bear low t...
Autores principales: | Thoms, Brendan L., Gosselin, Jeanne, Libman, Bonita, Littenberg, Benjamin, Budd, Ralph C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776555/ https://www.ncbi.nlm.nih.gov/pubmed/35079694 http://dx.doi.org/10.1007/s42399-022-01121-4 |
Ejemplares similares
-
Efficacy of Combination Therapy With The JAK Inhibitor Baricitinib In The Treatment of COVID-19
por: Thoms, Brendan Lawless, et al.
Publicado: (2021) -
A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience
por: Taylor, Peter C., et al.
Publicado: (2023) -
Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
por: Jabbari, Ali, et al.
Publicado: (2015) -
Successful treatment of ulcerated pyoderma gangrenosum with baricitinib, a novel JAK inhibitor
por: Scheinberg, Morton, et al.
Publicado: (2021) -
JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
por: Sanchez, Gina A. Montealegre, et al.
Publicado: (2018)